Tianjin TEDA Biomedical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 30 April 2026.

• Authorised share capital remained at 2.13 billion shares, split between 1.44 billion H Shares and 0.70 billion Domestic Shares, each with a par value of RMB 0.10. Total authorised capital therefore stayed at RMB 213.39 million.

• Issued share capital was unchanged at 2.13 billion shares, comprising 1.44 billion H Shares and 0.70 billion Domestic Shares. No treasury shares were held.

• The company confirmed that its H Share public float continued to meet the minimum 25% threshold required under Hong Kong listing rules.

• There were no share options, warrants, convertible securities, share repurchases or other equity movements during the reporting period.

The filing, submitted on 4 May 2026, underscores TEDA Biomedical’s unchanged capital structure and ongoing compliance with Hong Kong Exchange requirements.